Buchumschlag

A community challenge for a pancancer drug mechanism of action inference from perturbational profile data

The Columbia Cancer Target Discovery and Development (CTD2) Center is developing PANACEA, a resource comprising dose-responses and RNA sequencing (RNA-seq) profiles of 25 cell lines perturbed with ∼400 clinical oncology drugs, to study a tumor-specific drug mechanism of action. Here, this resource s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Douglass, Eugene F. (VerfasserIn) , Allaway, Robert J. (VerfasserIn) , Szalai, Bence (VerfasserIn) , Wang, Wenyu (VerfasserIn) , Tian, Tingzhong (VerfasserIn) , Fernández-Torras, Adrià (VerfasserIn) , Realubit, Ron (VerfasserIn) , Karan, Charles (VerfasserIn) , Zheng, Shuyu (VerfasserIn) , Pessia, Alberto (VerfasserIn) , Tanoli, Ziaurrehman (VerfasserIn) , Jafari, Mohieddin (VerfasserIn) , Wan, Fangping (VerfasserIn) , Li, Shuya (VerfasserIn) , Xiong, Yuanpeng (VerfasserIn) , Duran-Frigola, Miquel (VerfasserIn) , Bertoni, Martino (VerfasserIn) , Badia-i-Mompel, Pau (VerfasserIn) , Mateo, Lídia (VerfasserIn) , Guitart-Pla, Oriol (VerfasserIn) , Chung, Verena (VerfasserIn) , Tang, Jing (VerfasserIn) , Zeng, Jianyang (VerfasserIn) , Aloy, Patrick (VerfasserIn) , Sáez Rodríguez, Julio (VerfasserIn) , Guinney, Justin (VerfasserIn) , Gerhard, Daniela S. (VerfasserIn) , Califano, Andrea (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 18, 2022
In: Cell reports. Medicine
Year: 2022, Jahrgang: 3, Heft: 1, Pages: 1-13, e1-e7
ISSN:2666-3791
DOI:10.1016/j.xcrm.2021.100492
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.xcrm.2021.100492
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2666379121003694
Volltext
Verfasserangaben:Eugene F. Douglass, Robert J. Allaway, Bence Szalai, Wenyu Wang, Tingzhong Tian, Adrià Fernández-Torras, Ron Realubit, Charles Karan, Shuyu Zheng, Alberto Pessia, Ziaurrehman Tanoli, Mohieddin Jafari, Fangping Wan, Shuya Li, Yuanpeng Xiong, Miquel Duran-Frigola, Martino Bertoni, Pau Badia-i-Mompel, Lídia Mateo, Oriol Guitart-Pla, Verena Chung, Jing Tang, Jianyang Zeng, Patrick Aloy, Julio Saez-Rodriguez, Justin Guinney, Daniela S. Gerhard, and Andrea Califano
Beschreibung
Zusammenfassung:The Columbia Cancer Target Discovery and Development (CTD2) Center is developing PANACEA, a resource comprising dose-responses and RNA sequencing (RNA-seq) profiles of 25 cell lines perturbed with ∼400 clinical oncology drugs, to study a tumor-specific drug mechanism of action. Here, this resource serves as the basis for a DREAM Challenge assessing the accuracy and sensitivity of computational algorithms for de novo drug polypharmacology predictions. Dose-response and perturbational profiles for 32 kinase inhibitors are provided to 21 teams who are blind to the identity of the compounds. The teams are asked to predict high-affinity binding targets of each compound among ∼1,300 targets cataloged in DrugBank. The best performing methods leverage gene expression profile similarity analysis as well as deep-learning methodologies trained on individual datasets. This study lays the foundation for future integrative analyses of pharmacogenomic data, reconciliation of polypharmacology effects in different tumor contexts, and insights into network-based assessments of drug mechanisms of action.
Beschreibung:Gesehen am 20.12.2022
Beschreibung:Online Resource
ISSN:2666-3791
DOI:10.1016/j.xcrm.2021.100492

Ähnliche Einträge